Manero Marcén E, Malo Ocejo P, Uriarte Uriarte J J, Pinilla Tubet E
Servicio de Psiquiatría General Varones, Hospital Psiquiátrico Zamudio, Vizcaya.
Arch Neurobiol (Madr). 1992 Sep-Oct;55(5):235-40.
Creatine phosphokinase (CPK) is studied in psychiatric hospitalized patients under neuroleptic treatment in order to clarify the diagnostic value of this enzyme in the neuroleptic malignant syndrome (SNM). Intramuscular drug administration was, in the present study, the only variable associated with CPK levels over 1,000 U. Other items studied, like agitation, physical restraint or illness severity can not account for this elevation. In absence of i.m. medication, levels over 1,000 U must be carefully screened in order to rule out SNM or organic pathology associated.
为了阐明肌酸磷酸激酶（CPK）在抗精神病药物恶性综合征（SNM）中的诊断价值，对接受抗精神病药物治疗的精神科住院患者进行了研究。在本研究中，肌肉注射药物是与CPK水平超过1000 U相关的唯一变量。所研究的其他因素，如躁动、身体约束或疾病严重程度，均不能解释这种升高。在没有肌肉注射药物的情况下，必须仔细筛查超过1000 U的水平，以排除SNM或相关的器质性病变。
